D’Alise et al. showed that their neoantigen vaccine (Gad-CT26-31) in combination with anti-PD1 treatment provided complete tumour regression in advanced tumour stages of ~50% of mice and that combinational therapy was required to treat large established subcutaneous CT26 tumours [42]. Here, DDX53 is linked to neoplasm.